GO-Pen ApS

Our team is heading to Florence, Italy to participate in the Advanced Technologies & Treatments for Diabetes (ATTD) 2024 conference.   We’re looking forward to meeting current and future GO-Pen ApS partners at #booth28 to discuss innovation to create equal access to quality diabetes care.   Don’t miss the Tech Fair presentation ‘License to Treat: Unveiling GO-Pen’s Affordable Insulin Pen for All’ by our CCO Kristina Jensen. Attend Friday or Saturday: 🗓 Friday 8 March at 10:40 in the Exhibition Area 🗓 Saturday 9 March at 12:26 in Hall H    See full programme 👉  https://lnkd.in/gpHm6qBV We hope to see you there!   #Diabetes #T1D #T2D #DiabetesInnovation #ATTD2024

On the doorstep of a new year, I am both introspective and forward-looking. At GO-Pen, we're not just looking back at a great year in 2023; we're gearing up for the leaps ahead. Let me share with you a few highlights.    🚀 The launch of our European Innovation Council and SMEs Executive Agency (EISMEA) project, fueled by a substantial EU grant, catapulted us into a year of new development and set the stage for us to deliver an insulin pen for all. Despite the rigorous demands from the FDA, our submission of a 510(k) in August stands as a testimony to our commitment to navigate regulatory complexities with agility and resolve.   🤝 Our dialogue with regulatory bodies has been robust and challenging, yet it has propelled us towards greater precision and market readiness. We're not just ticking off milestones; we're learning, adapting, and preparing for the road ahead.   💡 Insight into the market has been a critical piece of our journey. Thanks to additional EU funding from INNOWWIDE, we've listened and learned from people who rely on insulin, healthcare providers, and payers. Our exploration has sharpened our market strategy and reminded us in a positive way of the unmet medical need we are aiming for.    🏆 Winning the American Diabetes Association's Innovation Challenge didn't just add a trophy to our cabinet - it reinforced our drive to redefine and deliver an insulin pen for all.    🚀 Our inclusion in StartUp Health's T1D Moonshot goes beyond support; it's an alliance with all who are making a difference for people with diabetes.   🌟 We have attracted passionate talents in Aparajita Tatke and Teo Meyer, who every day help us closer to reaching our goals.   🌐 Achieving #iso13485 certification was a major milestone that echoes our promise of quality and trust in every solution we craft.   🔄 Embracing #agile has marked a leap towards drive and efficiency, reflecting in every process we refine.   As we navigate towards regulatory approvals, our spirit remains undeterred. We're determined to deepen our partnerships, broaden our horizons with more GO-Pen variants, and continue to champion affordability and accessibility in diabetes care.   Our gratitude extends beyond words to the steadfast dedication of our team and the unwavering support of our partners. The challenges we face with regulatory processes only sharpen our focus and fortify our resolve.   2024 is not just another new year. It will be a year in which our commitment to excellence and innovation will hopefully meet the health of millions. Stay with us as we are embarking on a journey full of promise, innovation, and impact. Happy New Year, Ole Kjerkegaard Nielsen 🌟🔬 #Insulinpen4All #NewYearReflections #HealthcareInnovation #ExcitingJourneyAhead #Diabetes #Health4All 🚀  Laura Mandel Kristina Jensen Aparajita Tatke Teo Meyer

We have just joined the T1D (Type 1 Diabetes) moonshot launched by StartUp Health earlier this year. They wish to speed up progress on the prevention, management, and cure of Type 1 diabetes. We wish to help all people with diabetes using insulin to manage their diabetes and with this move, we will advance the progress of the GO-PEN journey, now with a wide host of newly found US-based friends.

🚀 Thrilled to be featured in a recent article by StartUp Health! 🎉 Our mission is to develop a low-cost, high-quality insulin pen for millions of people around the world. GO-Pen's design and long-lasting capability make it a cost-effective solution for those who rely on insulin injections with syringes. As we move towards regulatory clearance, we're seeking investors and commercial partners to join us on this exciting journey. Together, we can make a real impact on people's lives. Read the full article to learn more about our journey and vision for the future. #diabetes #DiabetesCare #HealthTech #Innovation #HealthcareSolutions